// Latest Publications:
199. Association of urinary EGF, FABP3, and VCAM1 levels with the progression of early diabetic kidney disease. Kidney Blood Press Res 2024 (in press) (IF 2.3)
Keller F, Denicolò S, Leierer J, Kruus M, Heinzel A, Kammer M, Ju W, Nair V, Burdet F, Ibberson M, Menon R, Otto E, Choi YJ, Pyle L, Ladd P, Bjornstad PM, Eder S, Rosivall L, Mark PB, Wiecek A, Heerspink HJL, Kretzler M, Oberbauer R, Mayer G, Perco P.
View PDF
198. Cilgavimab and Tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants – a prospective cohort study (RESCUE-TX). EBioMedicine 2024 (in press) (IF 9.7)
Reindl-Schwaighofer R, Heinzel A, Raab L, Strassl R, Herz CT, Regele F, Doberer K, Helk O, Spechtl P, Aschauer C, Hu K, Jagoditsch R, Reiskopf B, Böhmig GA, Benka B, Mahr B, Stiasny K, Weseslindtner L, Kammer M, Wekerle T, Oberbauer R.
View PDF
197. Initial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continents. Transpl Infect Dis 2024 (in press) (IF 2.6)
Coussement J, Bansal SB, Scemla A, Svensson MHS, Barcan LA, Smibert OC, Clemente WT, Lopez-Medrano F, Hoffman T, Maggiore U, Catalano C, Hilbrands L, Manuel O, DU Toit T, Shern TKY, Chowdhury N, Viklicky O, Oberbauer R, Markowicz S, Kaminski H, Lafaurie M, Pierrotti LC, Cerqueira TL, Yahav D, Kamar N, Kotton CN
View PDF